The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Title:
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Author:
Francis, K.E. Kim, S.I. Friedlander, M. Gebski, V. Ray-Coquard, I. Clamp, A. Penson, R.T. Oza, A. Perri, T. Huzarski, T. Martin-Lorente, C. Cecere, S.C. Colombo, N. Ataseven, B. Fujiwara, K. Sonke, G. Vergote, I. Pujade-Lauraine, E. Kim, J.-W. Lee, C.K.